Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)

Arnold W. Cohen, Joshua A. Copel, George A. MacOnes, M. Kathryn Menard, Laura Riley, George R. Saade

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)'. Together they form a unique fingerprint.

Medicine & Life Sciences